Santhera Pharmaceuticals Holding AG: Santhera and ReveraGen Announce FDA Acceptance of New Drug Application for Vamorolone in Duchenne Muscular Dystrophy

Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, and Rockville, MD, USA, January 9, 2023 - Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce that the

Related Keywords

Pratteln ,Switzerland General ,Switzerland ,United States ,United Kingdom ,France ,America ,Swiss ,Eric Hoffman ,Eva Kalias ,Reveragen Biopharma ,Dario Eklund ,Reveragen Biopharma Inc ,Life Science Alliance ,Santhera Pharmaceuticals ,Muscular Dystrophy Association United States ,National Institutes Of Health ,Duchenne Research Fund ,Foundation To Eradicate Duchenne ,Drug Administration ,Santhera Pharmaceuticals Holding ,Head Investor Relations Communications ,European Union ,European Medicines Agency ,Chiesi Group ,Us Department Of Defense ,Prescription Drug User Fee Act ,Orphan Drug ,Fast Track ,Rare Pediatric Disease ,Promising Innovative Medicine ,Proc Natl Acad Sci United States ,North America ,Parent Project Muscular Dystrophy ,Eradicate Duchenne ,Save Our Sons ,Action Duchenne ,Defeat Duchenne ,National Institutes ,Head Investor Relations ,Santhera ,Pharmaceuticals ,Molding ,Everagen ,Nnounce ,Acceptance ,Drug ,Application ,Vamorolone ,Duchenne ,Muscular ,Dystrophy ,